Results 51 to 60 of about 341,593 (314)

A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine. [PDF]

, 2017
BackgroundDFN-02 is a novel intranasal spray formulation composed of sumatriptan 10 mg and a permeation-enhancing excipient comprised of 0.2% 1-O-n-Dodecyl-β-D-Maltopyranoside (DDM).
Allenby, Kent, Brand-Schieber, Elimor, Cady, Roger K, Munjal, Sagar, Rapoport, Alan M, Spierings, Egilius LH   +5 more
core   +1 more source

Efficacy and safety of using eslicarbazepine in treating focal epilepsy in clinical practice (based on international Euro-Esli study and personal experience)

Эпилепсия и пароксизмальные состояния, 2020
The latest data on the eslicarbazepine (ESL) efficacy, tolerability and safety in treatment of focal epilepsy are presented based on the results of the European study in clinical practice Euro-Esli that enrolled 2058 patients from 14 European centers, a ...
I. A. Zhidkova, V. A. Karlov, P. N. Vlasov   +2 more
doaj   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

DFN-02, Sumatriptan 10 mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment. [PDF]

, 2019
BackgroundThe commercial formulation of sumatriptan nasal spray is an effective option for migraine patients requiring or preferring a non-oral route of drug administration, but its utility is limited by poor absorption and tolerability issues. DFN-02, a
Brand-Schieber, Elimor, Lipton, Richard B, Munjal, Sagar, Rapoport, Alan M   +3 more
core  

Patterns of management of patients with dual disorder (psychosis) in Italy: a survey of psychiatrists and other physicians focusing on clinical practice [PDF]

, 2018
© 2018 Clerici, de Bartolomeis, De Filippis, Ducci, Maremmani, Martinotti and Schifano. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).Patients with severe psychotic disorders such as ...
Acquas, Akiskal, Archie, Bacopoulos, Blum, Blum, Bowirrat, Carra, Connelly, Cuomo, De Bartolomeis, De Bartolomeis, Degenhardt, Delisi, Fantini, Fiorillo, Getzen, Gouzoulis-Mayfrank, Grob, Hertzog, Howes, Iasevoli, Kerner, Lambert, Maremmani, Martin, Martinotti, Nesvag, Ostuzzi, Papageorgiou, Regier, Roncero, Rovai, Rubino, Samaha, Samalin, Sugawara, Szkultecka-Debek, Ventriglio, Volkow   +39 more
core   +4 more sources

Effect size of lithium, carbamazepine, and sodium valproate in child and adolescent bipolar 1 disorder during manic phase: A prospective open-label study

Industrial Psychiatry Journal, 2019
Aim: The aim was to evaluate the “effect size (ES),” tolerability, and acceptability of lithium, carbamazepine, and sodium valproate in the acute phase treatment of pediatric Bipolar 1 disorder patients during manic phase.
Rakesh Kumar Singh, Vinod Kumar Sinha, Suprakash Chaudhury   +2 more
doaj   +1 more source

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview

Pharmaceuticals, 2020
Patients with hepatocellular carcinoma (HCC) face a common type of cancer, which is amongst the most deadly types of cancer worldwide. The therapeutic options range from curative resection or ablation to loco regional therapies in palliative setting and ...
Diederick J. van Doorn, Robert Bart Takkenberg, Heinz-Josef Klümpen   +2 more
doaj   +1 more source

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source

Angiotensin receptor blockers in heart failure after the ELITE II trial

Current Controlled Trials in Cardiovascular Medicine, 2000
Specific blockers of the angiotensin type1 receptor, angiotensin receptor blockers (ARBs), have been introduced as an alternative to angiotensin-converting enzyme inhibitors (ACEi) for the treatment of heart failure.
Willenheimer Ronnie
doaj   +1 more source

Keratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Keratin 19 (KRT19) is overexpressed in high‐grade serous ovarian cancer with high levels of Kallikrein‐related peptidases (KLK) 4–7 and is associated with poor survival. In vivo analyses demonstrate that elevated KRT19 increases peritoneal tumour burden.
Sophia Bielesch, Isabel Vogel, Sina Nokodian, Johanna Moeller, Antonia Blechschmidt, Vicky Hecht, Vanessa Kuentzel, Katharina Thiedig, Melissa Schwab, Oliver Schilling, Holger Bronger, Marion Kiechle, Viktor Magdolen, Tobias Dreyer   +13 more
wiley   +1 more source